University of Auckland

The University of Auckland is engaged in research on the therapeutic uses of psychedelic drugs, focusing on substances like LSD, ketamine, and MDMA to address mental health issues. This research is led by Dr. Suresh Muthukumaraswamy, who specializes in neuropsychopharmacology and brain imaging. His work includes exploring the impact of these substances on the brain and their potential to treat conditions such as depression, addiction, and the psychological distress of cancer patients.

Dr. Muthukumaraswamy’s research involves advanced brain imaging techniques to study the effects of psychedelic drugs. He has participated in significant studies in the UK, including producing the first images of the brain on LSD. The University of Auckland’s investigations into ketamine’s effects on the brain have shown promise for treating severe depression by increasing neural plasticity, which is crucial for reducing depressive symptoms​​​​​​.

Additionally, a trial is underway at the university to assess the benefits of psychedelic-assisted therapy for cancer patients dealing with existential distress​​. This trial reflects a broader interest in how psychedelics can provide relief from psychological suffering in contexts beyond traditional mental health diagnoses.

These studies are part of a wider resurgence in psychedelic research, which seeks to understand how these substances can be integrated into therapeutic practices. The research at the University of Auckland aims to contribute to a growing body of evidence suggesting that, under controlled conditions, psychedelic substances may offer significant benefits in treating a range of mental health conditions, with ongoing exploration into their mechanisms of action and therapeutic potential​​.